Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 8/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26374615 | 1.00 | ALDH1A1 (0.39) | ALDH1A1LMNAGLSGBA1CYP3A4 | |
| SCHEMBL23627235 | 0.99 | ALDH1A1 (0.40) | ALDH1A1LMNAGLSGBA1CYP3A4 | |
| SCHEMBL26374542 | 0.95 | ALDH1A1 (0.40) | ALDH1A1LMNAGLSCYP3A4MAPT | |
| SCHEMBL9325575 | 0.89 | ALDH1A1 (0.42) | ALDH1A1LMNAGLSCYP3A4HPGD | |
| SCHEMBL26381267 | 0.87 | ALDH1A1 (0.44) | ALDH1A1LMNAHPGDSMN1; SMN2GLA | |
| SCHEMBL23627266 | 0.86 | ALDH1A1 (0.39) | ALDH1A1LMNAGLSCYP3A4HPGD | |
| SCHEMBL26381323 | 0.84 | ALDH1A1 (0.43) | ALDH1A1LMNAGLSGBA1HPGD | |
| SCHEMBL26374612 | 0.83 | ALDH1A1 (0.37) | ALDH1A1LMNAGLSCYP3A4HPGD | |
| SCHEMBL26374595 | 0.83 | ALDH1A1 (0.37) | ALDH1A1LMNAGLSCYP3A4HPGD | |
| SCHEMBL26374578 | 0.81 | ALDH1A1 (0.37) | ALDH1A1LMNAGLSCYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| WO-2021137646-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | 주식회사 레고켐바이오사이언스 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | BCR, PDCD1LG2, PRLHR | ALDH1A1 1636/4885LMNA 4012/4885GLS 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.